Group 1 - The company has been included in multiple indices, such as the Hang Seng Composite Index (HSCI), Hang Seng Hong Kong Stock Connect Index, and Hang Seng Innovative Drug Index, effective March 9, 2026 [1] - The inclusion in the MSCI Global Small Cap Index will take effect after the market closes on February 27, 2026, reflecting the company's growing recognition in the market [1] - The Hang Seng Composite Index covers the top 95% of companies listed on the Hong Kong Stock Exchange, making it a significant benchmark for index funds and performance evaluation [1] Group 2 - The company will also be included in various other Hang Seng indices, such as the Hang Seng Composite Small Cap Index and the Hang Seng Healthcare Index, indicating broad market acceptance [2] - The board believes that inclusion in these important indices demonstrates investor recognition of the company's value and growth potential, which is expected to enhance stock liquidity and diversify the shareholder base [2] - The company aims to strengthen its leading position in the RAS sector and enhance its international competitiveness in innovative drug fields, driving value creation through its R&D advantages [2]

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Baoyi Pharmaceutical-B (02659) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Company Summary - Baoyi Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, the world's first IgG degrading enzyme KJ103 with "best-in-class" potential in low pre-storage antibodies and dosing frequency for antibody-mediated autoimmune diseases, and a long-acting follicle-stimulating hormone drug SJ02 for assisted reproduction, indicating a transition from pure R&D to commercialization [1] - The inclusion in the Hang Seng Composite Index is expected to enhance stock liquidity and valuation premium, providing mainland investors with opportunities to allocate quality biopharmaceutical assets [1]

董事会进一步宣布，经考虑审核委员会的推荐意见，董事会已议决批准委任栢淳会计师事务所有限公司 (栢淳)为本公司新任核数师，以填补国富浩华辞任后产生的临时空缺，自2026年2月13日起生效，并将 任职至本公司下一届股东周年大会结束为止。 裕承科金(00279)发布公告，由于本公司与国富浩华(香港)会计师事务所有限公司(国富浩华)未能就本集 团截至2026年3月31日止年度的综合财务报表审核费用达成共识，国富浩华已辞任本公司核数师，自 2026年2月13日起生效。 ...

Core Insights - The health industry is experiencing unprecedented growth opportunities due to factors such as an aging global population, the prevalence of chronic diseases, rising consumer awareness, and innovations in artificial intelligence (AI) and digital technology [1][2] - In China, the aging process and widespread application of digital technology are expanding the "silver economy" within the health market [1] - The company aims to develop health, digital medical, and wellness services in response to the national "Healthy China" strategy, focusing on a three-dimensional health service ecosystem that transitions health management from "disease treatment" to "prevention and maintenance" [1] Group 1 - The company has recently completed the acquisition of Zhongshan Yuanqi Smart Health Technology Co., Ltd. and formed a research and development team composed of professionals in data science and health management [1] - This team will focus on health data analysis and intelligent services, developing a one-stop health management platform for real-time monitoring of health data across all demographics and life stages [1] - The platform will leverage general artificial intelligence (AGI) technology to promote healthy lifestyles and concepts to users [1] Group 2 - The platform is planned to integrate dynamic vital sign monitoring, intelligent risk assessment, personalized health interventions, and medication reminders, with connections to medical institutions, wellness service providers, and home care scenarios [2] - The company plans to increase investment in general artificial intelligence and big data systems in the health sector over the next three years to continuously advance technology iteration and platform optimization [2] - Once operational, the platform is expected to significantly enhance the company's revenue annually and gradually establish a dual-driven profit model through technology output and service subscriptions [2]

滴普科技公布，于2025年12月17日，该公司与沐曦集成电路(上海)股份有限公司(沐曦股份)订立战略合 作协议，旨在利用双方各自的优势及资源，在企业级大模型AI应用领域方面深化战略合作关系。根据 战略合作协议，双方将根据自身优势资源，聚焦制造、商业流通、交通、医疗等关键行业数智化需求， 成立联合技术攻关团队，打造从底层硬件算力平台到 AI级企业操作系统以及Agentic AI应用的全栈国产 AI端到端解决方案。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中滴普科技(01384) 获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效， 届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，滴普科技有可能被调入港股通，因其 满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

博雷顿(01333)发布公告，于2026年2月13日斥资1498.79万港元回购71.08万股。 ...

Group 1 - The company HuTongDa Network (09878) announced the acquisition of a 25% stake in JinTongLing (300091.SZ), with the target company's restructuring plan completed as of the announcement date [1] - The target company is a leading industrial service enterprise in China, focusing on digital technology and supply chain capabilities to empower rural retail stores [1] - The company aims to enhance the living standards of farmers through innovative supply chain and digital services, promoting the "integration of production and sales" strategy [1] Group 2 - The target company specializes in manufacturing fluid machinery, including industrial blowers and high-efficiency steam turbines, with applications in various industries such as wastewater treatment and food preservation [2] - The acquisition aligns with the company's overall strategic direction and will strengthen the synergy and value enhancement of existing business segments [2] - The company plans to nominate a majority of the board members of the target company and appoint key management personnel to lead daily operations and strategic decisions [2]

Core Viewpoint - Airbnb (ABNB.US) reported a strong performance in Q4, with revenue growth exceeding market expectations, indicating robust demand in the travel and hospitality sector [1] Financial Performance - Q4 revenue increased by 12% year-over-year to $2.78 billion, surpassing market expectations of $2.71 billion [1] - The number of booked nights and experiences rose by 10% year-over-year to 121.9 million, exceeding the market forecast of 117.6 million [1] - Total booking value grew by 16% year-over-year to $20.4 billion, also above the expected $19.4 billion [1] Future Outlook - For Q1, Airbnb projects revenue between $2.59 billion and $2.63 billion, higher than the market expectation of $2.53 billion [1]

Core Viewpoint - Coinbase reported a significant decline in revenue and a net loss for Q4, but projects substantial growth in trading volume and profitability for 2025 [1] Financial Performance - Q4 revenue decreased by 20% to $1.8 billion, exceeding market expectations [1] - The company recorded a net loss of $667 million for the quarter, compared to a net profit of $1.3 billion in the same period last year [1] - The loss was primarily attributed to impairment charges related to cryptocurrency holdings and investments [1] Future Projections - Coinbase anticipates total trading volume to exceed $5.2 trillion in 2025, representing a year-over-year growth of 156% [1] - The company expects to achieve a net profit of approximately $1.26 billion for the full year of 2025 [1] Market Share - Coinbase's market share in the spot market doubled, increasing from 3.2% at the end of 2024 to 6.4% [1]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Health 160 (02656) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its establishment [1]